Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

By B. Alexander, Melissa D. Johnson, C. Pfeiffer, Cristina Jimenez-Ortigosa, J. Catania, R. Booker, Mariana Castanheira, S. Messer, D. Perlin, M. Pfaller. Clinical Infectious Diseases, 2013

757 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/602994a6a7d31fd45a531977af77372f1c4aeb38

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Immunology

M. Ghannoum

In Infectious Diseases

Citations in the corpus

Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment (2017, background): “A report from one US medical center demonstrated that over a 10 year-period, echinocandin resistance rose from 2%–3% to >13% in 2009–2010 [34].”
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “complicates the selection of antifungal therapy for the immediate future [10, 12, 35–38] as there are no good prospective data to guide therapy.”
Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 (2019, background): “Although the MDR phenotype is most often detected after prolonged exposure to both classes of agents [1, 6, 26, 65, 68, 70], recent studies have demonstrated that under stress conditions, MSH2 DNA mismatch repair gene mutations may produce a hypermutable state and facilitate rapid acquisition of flu”
Resistance of Candida to azoles and echinocandins worldwide. (2019, background): “glabrata isolates that have increased resistance to echinocandins have mutations in the FKS1 or FKS2 gene, or both [5,17,25,31].”